Journal
TRENDS IN PHARMACOLOGICAL SCIENCES
Volume 41, Issue 11, Pages 868-881Publisher
CELL PRESS
DOI: 10.1016/j.tips.2020.09.001
Keywords
-
Categories
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases [R01DK107641, R01DK120309]
Ask authors/readers for more resources
Metformin can improve patients' hyperglycemia through significant suppression of hepatic glucose production. However, up to 300 times higher concentrations of metformin accumulate in the intestine than in the circulation, where it alters nutrient metabolism in intestinal epithelial cells and microbiome, leading to increased lactate production. Hepatocytes use lactate to make glucose at the cost of energy expenditure, creating a futile intestine-liver cycle. Furthermore, metformin reduces blood lipopolysaccharides and its initiated low-grade inflammation and increased oxidative phosphorylation in liver and adipose tissues. These metformin effects result in the improvement of insulin sensitivity and glucose utilization in extrahepatic tissues. In this review, I discuss the current understanding of the impact of metformin on systemic metabolism and its molecular mechanisms of action in various tissues.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available